
Invert provides software that turns fragmented bioprocess time-series data into clear, actionable insights so teams can make faster, more confident decisions. The platform unifies and contextualizes data from instruments, sites, and CDMOs, eliminates manual cleanup, and creates AI-ready datasets. Built as a Bioprocess AI SaaS, Invert includes built-in visualization, analytics, and a transparent AI interface to deliver real-time, AI-driven recommendations. Biotech, pharmaceutical, and manufacturing companies use the system to accelerate development, de-risk scale-up, and shorten time to milestones.

Invert provides software that turns fragmented bioprocess time-series data into clear, actionable insights so teams can make faster, more confident decisions. The platform unifies and contextualizes data from instruments, sites, and CDMOs, eliminates manual cleanup, and creates AI-ready datasets. Built as a Bioprocess AI SaaS, Invert includes built-in visualization, analytics, and a transparent AI interface to deliver real-time, AI-driven recommendations. Biotech, pharmaceutical, and manufacturing companies use the system to accelerate development, de-risk scale-up, and shorten time to milestones.
Product: Bioprocess data management and Bioprocess AI SaaS for collecting, cleaning, contextualizing, analyzing, and modeling time-series bioprocess data
Founded: 2021
Latest fundraise: Seed (announced 2024-07-10), ~$20.2M reported
Investors: Giant Ventures; Y Combinator
Compliance / security: States SOC 2 Type II and ISO 27001 alignment; supports 21 CFR Part 11 / EU Annex 11 traceability
| Company |
|---|
Bioprocess data fragmentation, manual data cleanup, and lack of AI-ready datasets for process development and scale-up.
2021
Biotechnology Research
$20.2M
Reported as Seed round announced Jul 10, 2024; total funding reported across 3 rounds on company profiles.
“Giant Ventures; Y Combinator”